Sunday February 24, 2019

Melatonin May Help Treat Blood Cancers like Leukemia and Lymphoma, Claims a New Research

The researchers have noted that the anti-cancer actions of melatonin will be helpful in facilitating clinical applications and basic research

0
//
Melatonin produced by a gland in the brain can help treat blood cancers
Melatonin may help treat blood cancers. Pixabay
  • Researchers have discovered that Melatonin may help treat blood cancers like leukemia and lymphoma 
  • Melatonin’s involvement in regulation of circadian rhythms may help in coordination and synchronization of internal body functions 
  • Anti-cancer actions of melatonin are expected to be helpful in facilitating basic research 

Washington D.C. [USA], September 3, 2017: Researchers have discovered that blood cancers such as leukemia and lymphoma may be treated with a hormone produced by a small gland in the brain.

Melatonin, a hormone produced by a small gland in the brain may be able to treat blood cancers like leukemia and lymphoma, according to the researchers.

The findings suggest that melatonin performs a number of tasks such as boosting the immune response against cancer cells, inhibiting the growth of cancer cells and even protecting the healthy cells from chemotherapy’s toxic effects.

Melatonin’s involvement in regulation of circadian rhythms may help in the coordination and synchronization of internal body functions. The timings of he melatonin treatment may be grave in regard to their anti-cancer effects.

Senior author Yang Yang hopes that this information would prove helpful in the design of studies concerned with the therapeutic efficiency of melatonin in blood cancers.

Also read: Arthritis drug could cure blood cancer: Researchers

The researchers have noted that the anti-cancer actions of melatonin will be helpful in facilitating clinical applications and basic research.

The study has appeared in British Journal of Pharmacology.

-prepared by Samiksha Goel of NewsGram. Twitter @goel_samiksha

Next Story

Study Reveals Shorter Duration of Radiation Safe in Treating Prostate Cancer

This method is both safe and effective and could be a viable treatment option for men with low and intermediate-risk of prostate cancer, the study suggested.

0
cancer
The study showed that this type of radiation - stereotactic body radiotherapy - is a form of external beam radiation therapy, which reduces the duration of treatment from 45 days to four to five days with no evidence of causing worse toxicity in the long run. Pixabay

Men with low or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period of time and still have the same, successful outcomes as from a much longer course of treatment, according to researchers including one of Indian-origin.

The study showed that this type of radiation – stereotactic body radiotherapy – is a form of external beam radiation therapy, which reduces the duration of treatment from 45 days to four to five days with no evidence of causing worse toxicity in the long run.

“Most men with low or intermediate-risk prostate cancer undergo conventional radiation, which requires them to come in daily for treatment and takes an average of nine weeks to complete,” said lead author Amar Kishan, Assistant Professor at University of California, Los Angeles, in the US.

smoking
Nearly, 53 per cent men had low-risk disease, 32 per cent had less aggressive intermediate-risk disease and 12 per cent had a more aggressive form of intermediate-risk disease. Pixabay

“With the improvements being made to modern technology, we have found that using stereotactic body radiotherapy, which has a higher dose of radiation, can safely and effectively be done in a much shorter timeframe without additional toxicity or compromising any chance of a cure,” said Kishan.

For the study, the team included 2,142 men with low or intermediate-risk prostate cancer who were treated with stereotactic body radiotherapy. They were followed for a median of 6.9 years.

Nearly, 53 per cent men had low-risk disease, 32 per cent had less aggressive intermediate-risk disease and 12 per cent had a more aggressive form of intermediate-risk disease.

cancer
These are essentially identical to rates following more conventional forms of radiation, which are about 4-5 per cent for low-risk disease and 10 per cent to 15 per cent for intermediate-risk disease. Pixabay

In addition, the recurrence rate for men with low-risk disease was 4.5 per cent, 8.6 per cent for the less aggressive intermediate-risk, and 14.9 per cent for the more aggressive intermediate-risk group, findings published in the journal JAMA Network Open showed.

Overall, the recurrence rate for intermediate-risk disease was 10.2 per cent.

Also Read: Facebook to Come up with ‘Unsend’ Feature on Messenger

These are essentially identical to rates following more conventional forms of radiation, which are about 4-5 per cent for low-risk disease and 10 per cent to 15 per cent for intermediate-risk disease.

This method is both safe and effective and could be a viable treatment option for men with low and intermediate-risk of prostate cancer, the study suggested. (IANS)